Af­ter spurn­ing Sanofi for di­a­betes dis­ap­point­ment, Zealand nets FDA ap­proval in se­vere hy­po­glycemia

About two and a half years af­ter sell­ing off roy­al­ties on a dis­ap­point­ing Sanofi-part­nered di­a­betes drug, Zealand Phar­ma now has its own in-house pro­gram to boast about.

Zealand re­ceived FDA ap­proval for dasiglucagon to treat se­vere hy­po­glycemia in chil­dren and adults with di­a­betes old­er than 6 years, the Dan­ish biotech an­nounced Mon­day. The drug will be called Ze­ga­logue and a com­mer­cial launch is ex­pect­ed in late June.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.